Fortelyzin
Showing 1 - 5 of 5
Acute Limb Ischemia Trial in Russian Federation (Recombinant non-immunogenic staphylokinase (Fortelyzin®), surgical methods of
Recruiting
- Acute Limb Ischemia
- Recombinant non-immunogenic staphylokinase (Fortelyzin®)
- surgical methods of treatment
-
Kazan, Republic Of Tatarstan, Russian Federation
- +5 more
Jan 19, 2023
Ischemic Stroke Trial in Russian Federation (Recombinant staphylokinase, Alteplase)
Completed
- Ischemic Stroke
- Recombinant staphylokinase
- Alteplase
-
Barnaul, Russian Federation
- +17 more
Dec 11, 2020
Massive Pulmonary Embolism Trial in Russian Federation (Recombinant nonimmunogenic staphylokinase, Alteplase)
Recruiting
- Massive Pulmonary Embolism
- Recombinant nonimmunogenic staphylokinase
- Alteplase
-
Barnaul, Russian Federation
- +16 more
Feb 7, 2022
COVID-19 Trial in Moscow (Recombinant nonimmunogenic staphylokinase, Placebo)
Suspended
- COVID-19
- Recombinant nonimmunogenic staphylokinase
- Placebo
-
Moscow, Russian Federation
- +1 more
Oct 25, 2022
Myocardial Infarction Trial in Russian Federation (Recombinant staphylokinase, Tenecteplase)
Unknown status
- Myocardial Infarction
- Recombinant staphylokinase
- Tenecteplase
-
Tomsk, Siberia, Russian Federation
- +15 more
Nov 25, 2014